CJC-1293
A modified GHRH analog similar to CJC-1295. Stimulates growth hormone release for research purposes.
Research Status
Early Research
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Erythema, mild swelling, or discomfort at the injection site typically resolves within 24 hours. Rotate injection sites to minimize local irritation. Apply ice if swelling persists.
Transient flushing may occur within 15-30 minutes of injection due to GH-mediated vasodilation. Usually self-resolving within 30-60 minutes.
Mild headache has been reported in some research subjects. Typically mild and transient; consider hydration and rest. Discontinue if severe or persistent.
GH is diabetogenic and may impair insulin sensitivity or elevate fasting glucose, particularly at higher doses or in predisposed individuals. Monitor fasting glucose and HbA1c; discontinue if clinically significant hyperglycemia develops.
Prolonged GH elevation may cause fluid retention and nerve compression in the carpal tunnel. Symptoms include wrist pain, numbness, or tingling. Seek medical evaluation if symptoms develop.
Myalgia or arthralgias have been reported in some users, possibly related to rapid changes in GH or IGF-1 levels. Usually mild and self-resolving; consider dose reduction if severe.
GH promotes sodium and water retention, potentially causing mild peripheral edema or weight gain. Typically mild and reversible upon discontinuation.
Repeated injections at the same site may cause localized fat loss (lipoatrophy) or fat thickening (lipohypertrophy). Strict site rotation prevents this complication.
Mild nausea has been reported in some research subjects. Usually transient and self-resolving; consider taking the injection with food if nausea occurs.
Transient dizziness may occur immediately after injection. Sit or lie down if this occurs; symptoms typically resolve within minutes.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 100-300 mcg |
| Frequency | 1-3x daily |
| Timing | Before bed, before meals, or post-exercise |
| Route | Subcutaneous |
Start at 100 mcg once daily and titrate upward based on response. CJC-1293 is a research compound; clinical efficacy and optimal dosing in humans remain under investigation. Typical research protocols use 100-200 mcg per injection.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Half-life | Approximately 7-10 days (extended compared to native GHRH, which has a half-life of 2-4 minutes) |
CJC-1293 is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. This binding stimulates the synthesis and secretion of growth hormone (GH), which in turn promotes the hepatic production of insulin-like growth factor-1 (IGF-1). The extended half-life of CJC-1293 (compared to native GHRH) results from modifications that enhance resistance to enzymatic degradation, allowing for less frequent dosing while maintaining sustained GH and IGF-1 elevation.
GHRH Receptor Signaling
CJC-1293 activates GHRH receptors on anterior pituitary somatotrophs, triggering intracellular cAMP accumulation and calcium mobilization, which stimulates GH synthesis and secretion into systemic circulation.
Growth Hormone — IGF-1 Axis
Elevated circulating GH acts on hepatic GH receptors to promote IGF-1 synthesis and release. IGF-1 mediates many anabolic effects of GH, including protein synthesis, lipolysis, and bone formation.
Feedback Regulation
Elevated GH and IGF-1 provide negative feedback to the hypothalamus and pituitary, reducing GHRH and GH secretion. This homeostatic mechanism limits excessive GH elevation.
- CJC-1293 is a GHRH analog with amino acid modifications that confer resistance to enzymatic degradation
- The extended half-life permits less frequent dosing compared to native GHRH or shorter-acting GHRH analogs
- GH secretion occurs in a pulsatile pattern; CJC-1293 enhances the amplitude and frequency of endogenous GH pulses
- IGF-1 elevation is the primary mechanism underlying the anabolic and metabolic effects attributed to GH secretagogues
- CJC-1293 does not directly suppress somatostatin (the endogenous GH-inhibiting hormone), distinguishing it from some other secretagogues
Track your CJC-1293 research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. CJC-1293 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.